| Literature DB >> 27965802 |
Vijay K Tailor1, Selina Glaze2, Payal Khandelwal2, Alison Davis1, Gillian G W Adams1, Wen Xing1, Catey Bunce1, Annegret Dahlmann-Noor3.
Abstract
BACKGROUND: Amblyopia ("lazy eye") is the commonest vision deficit in children. If not fully corrected by glasses, amblyopia is treated by patching or blurring the better-seeing eye. Compliance with patching is often poor. Computer-based activities are increasingly topical, both as an adjunct to standard treatment and as a platform for novel treatments. Acceptability by families has not been explored, and feasibility of a randomised controlled trial (RCT) using computer games in terms of recruitment and treatment acceptability is uncertain.Entities:
Keywords: Amblyopia; Child; Clinical trial
Year: 2015 PMID: 27965802 PMCID: PMC5154044 DOI: 10.1186/s40814-015-0018-y
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Fig. 1Consort flowchart of recruitment, allocation of intervention and 12-week analysis
Participant characteristics
| Standard ( | Eye five ( | Nintendo ( | |
|---|---|---|---|
| Gender, | 13(65) | 12(63) | 12(63) |
| Males | 7(35) | 7(37) | 7(37) |
| Females | |||
| Age (years), median (IQR) | 5.1(3.5–6) | 5.1(3.5–6.1) | 4.3(4–5.4) |
| Type of amblyopia | 5(25) | 11(57.9) | 8(42.1) |
| Anisometropic | 6(30) | 5(26.3) | 5(26.3) |
| Strabismus | 8(40) | 2(10.5) | 6(31.6) |
| Mixed | 1(5) | 1(5.3) | |
| Unknown | |||
| Severity of Amblyopia | 11(55) | 13(68.4) | 13(72.2) |
| Moderate | 9(45) | 6(11.6) | 6(27.8) |
| Severe |
Hours spent on prescribed near activity and reported hours of occlusion treatment at the 6- and 12-week review
| Compliance median (IQR) | Standard ( | Eye 5 ( | Nintendo ( | Total ( |
|---|---|---|---|---|
| Cumulative hours of near activity | ||||
| Moderate amblyopia 0–6 wks | 42 (21–48), | 39 (11–43), | 42 (32–54), | 42 (21–48), |
| Severe amblyopia 0–6 wks | 23 (8–39), | 29 (9–42), | 12 (8–18), | 20 (8–40), |
| Moderate amblyopia 0–12 wks | 77 (63–84), | 76 (30–84), | 79 (68–99), | 79 (61–84), |
| Severe amblyopia 0–12 wks | 49 (24–81), | 70 (34–82), | 24 (17–118), | 54 (17–82), |
| Cumulative hours of occlusion | ||||
| Moderate amblyopia 0–6 wks | 84 (60–88), | 66 (36–82), | 74 (46–82), | 72 (51–84), |
| Severe amblyopia 0–6 wks | 74 (64–145), | 84 (61–94), | 96 (86–126), | 85 (64–98), |
| Moderate amblyopia 0–12 wks | 158 (126–180), | 139 (97–164), | 156 (93–168), | 153 (108–168), |
| Severe amblyopia 0–12 wks | 190 (141–292), | 146 (125–159), | 351 (160–432), | 168 (142–351), |
N = total number of patients in the study arm, n = number of patients in the group with valid data (only shown when there is invalid or missing data); The prescribed numbers of hours of near activity use were 42 at 6 and 84 at 12 weeks. Children with moderate amblyopia used the prescribed near activity markedly more than children with severe amblyopia. The prescribed numbers of hours of occlusion at 6 weeks were 84 for moderate and 252 for severe amblyopia and at 12 weeks 168 and 504 h, respectively. Despite the difference in prescribed hours, effective hours reported in the diaries were similar in children with moderate and severe amblyopia
IQR interquartile range
BCVA and stereoacuity at 6 and 12 weeks
| Visual outcomes | Standard ( | Eye 5 ( | Nintendo( | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline BCV | Severe | Moderate | None | Severe | Moderate | None | Severe | Moderate | None |
| Amblyopic or non-amblyopic eyes | |||||||||
| 0.8 (0.8–1) | 0.36 (0.32–0.5) | 0.1 (0.01–0.12) | 0.76 (0.7–0.78) | 0.35 (0.3–0.5) | 0.1 (0.05–0.14) | 0.8 (0.7–0.9) | 0.4 (0.32–0.46) | 0.1 (0.02–0.12) | |
| 6 weeks VA | Severe | Moderate | None | Severe | Moderate | None | Severe | Moderate | None |
| Amblyopic or non-amblyopic eyes | |||||||||
| 0.6 (0.59–0.89) | 0.22 (0.06–0.4) | 0.1 (0–0.15) | 0.62 (0.58–0.75) | 0.25 (0.19–0.31) | 0.06 (0.05–0.12) | 0.5 (0.5–0.7) | 0.25 (0.2–0.38) | 0.1 (0–0.1) | |
| 12 weeks VA | Severe | Moderate | None | Severe | Moderate | None | Severe | Moderate | None |
| Amblyopic or non-amblyopic eyes | |||||||||
| 0.53 (0.47–0.73) | 0.28 (0.12–0.4) | 0.1 (0–0.14) | 0.5 (0.46–0.59) | 0.15 (0.1–0.2) | 0.06 (0.02–0.1) | 0.54 (0.5–0.58) | 0.14 (0.1–0.31) | 0.01 (0–0.1) | |
| Stereopsis | |||||||||
| Baseline | 0 (0–155) | 110 (0–170) | 110 (0–480) | ||||||
| 6 weeks | 0 (0–170), | 85 (0–170), | 110 (70–170), | ||||||
| 12 weeks | 0 (0–100), | 85 (0–100), | 85 (0–110), | ||||||
N = total number of patients in the study arm, n = number of patients in the group with valid data (only shown when there is invalid or missing data); At 12 weeks, median BCVA in children with severe amblyopia in the standard advice group improved by 0.27, in the Eye Five group by 0.26 logMar and in the Nintendo group by 0.26 logMar. In children with moderate amblyopia, median BCVA improved by 0.08, 0.2 and 0.26 logMar, respectively. Change in stereoacuity was small, if any
IQR interquartile range